Clinical trials: Stage III Lung Non-Small Cell Cancer AJCC v7
Non Small Cell Lung Cancer, Stage I Lung Cancer
High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer
This trial studies how well high dose vitamin A compound works in treating participants with non-small cell lung cancer that can be removed by surgery.
- Conditions
- Non Small Cell Lung Cancer, Stage I Lung Cancer, Stage Ib Lung Carcinoma, Stage IA Lung Carcinoma AJCC V7
- Trial name
- NCT03870529
- Testing
- Vitamin A Compound, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Carcinoma, Non-Small-Cell Lung
A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving Durvalumab
Objective in this study is to investigate feasibility of developing machine-learning based model for the identification of future development of diagnosed Grade 2 and higher ILD and of disease progression in patients with…
- Trial name
- iDETECT (NCT04884269)
- Where
- 27 sites in Japan
- Volunteers
- 144 people
- Sponsor
- AstraZeneca
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent).
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT03191149
- Testing
- Biospecimen Collection, Computed Tomography with Contrast, Echocardiography Test
- Where
- 347 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7
Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
This phase I trial studies the side effects and the best dose of trametinib when given together with combination chemotherapy and radiation therapy in treating patients with stage III non-small cell lung cancer that cannot be…
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT01912625
- Testing
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Image Guided Radiation Therapy
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
ALK Gene Rearrangement, ALK Gene Translocation
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma…
- Conditions
- ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- Trial name
- NCT02201992
- Testing
- Clinical Observation, Crizotinib, Laboratory Biomarker Analysis
- Where
- 1,618 sites in United States, Guam and 1 more
- Volunteers
- 166 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Stage IV Melanoma, Advanced Lung Cancer
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer.
- Conditions
- Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- UPLIFT (NCT04670445)
- Testing
- Educational Video and QPL List, Usual Care
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Lung Cancer
Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery
RATIONALE: Vaccines made from a gene-modified virus may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from…
- Trial name
- NCT00091039
- Testing
- recombinant fowlpox GM-CSF vaccine adjuvant, recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
NSCLC (Non-small Cell Lung Cancer)
Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
This phase II trial employs a prospective, randomized, parallel-group design to evaluate the efficacy and safety of hypofractionated radiotherapy combined with tislelizumab and surufatinib.
- Trial name
- NCT07609121
- Testing
- Radiotherapy, Concurrent chemotherapy, Tislelizumab
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of 6,8-bis(benzylthio)octanoic acid (CPI-613) when given together with docetaxel and to see how well they work in treating patients with stage IIIB or IV non-small cell…
- Trial name
- NCT03370159
- Testing
- 6,8-Bis(benzylthio)octanoic Acid, Docetaxel, Pharmacological Study
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Non-small Cell Lung Cancer
Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer
The current standard of care for unresectable locally advanced non-small-cell lung cancer (NSCLC) is a combination of chemotherapy and thoracic radiotherapy (TRT).
- Trial name
- NCT02407366
- Testing
- Icotinib, Pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- People's Hospital of Guangxi Zhuang Autonomous Region
Carcinoma, Non-Small-Cell Lung
A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
The goal of this phase II, open-label, single-arm study is to evaluate the efficacy and safety of induction immunotherapy and chemotherapy followed by the multidisciplinary team (MDT)-guided radiotherapy or surgery in…
- Trial name
- NCT05940532
- Testing
- Sugemalimab and Chemotherapy
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Hunan Cancer Hospital
Stage IIIA Non-small Cell Lung Cancer
Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
RATIONALE: Specialized radiation therapy, such as proton beam radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue in patients with…
- Trial name
- NCT01076231
- Testing
- proton beam radiation therapy, cisplatin, etoposide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non-small Cell Lung Cancer
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
To assess the efficacy and safety of Almonertinib versus placebo following chemoradiation in patients with stage III unresectable epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).
- Trial name
- NCT04951635
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Cancer Stage III
Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
The purpose of this study is to studying neoadjuvant IBI308, bevacizumab, plus pemetrexed and carboplatin followed by surgery to see how well it works in treating patients with unresectable stage III non-small cell lung cancer.
- Trial name
- NIBCUN (NCT03872661)
- Testing
- IBI308, Bevacizumab, Pemetrexed
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
RATIONALE: Vaccines made from mutated ras peptides may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune…
- Conditions
- Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer
- Trial name
- NCT00019006
- Testing
- Detox-B adjuvant, ras peptide cancer vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7
Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer
This phase I trial studies the side effects and best dose of nintedanib when given together with cisplatin and docetaxel and to see how well they work in treating patients with previously untreated stage IB-IIIA non-small cell…
- Conditions
- Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7
- Trial name
- NCT02225405
- Testing
- Cisplatin, Docetaxel, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer
Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)
OBSTINATE is an observational, national, prospective, multicentric study on Quality of life in patients with unresecable stade III non-small cell lung cancers.
- Trial name
- OBSTINATE (NCT05049044)
- Testing
- Quality of Life Questionnaire-Core 30 (QLQ-C30)
- Where
- 34 sites in France
- Volunteers
- 413 people
- Sponsor
- Groupe Francais De Pneumo-Cancerologie
Lung Cancer
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer
RATIONALE: Vaccines made from a person's white blood cells and allogeneic tumor cells may make the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00103116
- Testing
- autologous dendritic cell cancer vaccine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Edward Hirschowitz
Non-Small Cell Lung Cancer
Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial
This is a prospective, single-arm, multicenter phase II clinical study evaluating the efficacy and safety of spatially fractionated radiotherapy (SFRT) combined with tislelizumab and platinum-based doublet chemotherapy as…
- Trial name
- NCT07775040
- Testing
- Spatially Fractionated Radiotherapy (SFRT), Tislelizumab, Carboplatin
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Lung Cancer
Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00248495
- Testing
- cisplatin, pemetrexed disodium, adjuvant therapy
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Roswell Park Cancer Institute